Format

Send to

Choose Destination
See comment in PubMed Commons below
Rheumatology (Oxford). 2013 Jan;52(1):5-14. doi: 10.1093/rheumatology/kes189. Epub 2012 Jul 23.

Malignancy as a comorbidity in rheumatic diseases.

Author information

1
Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.

Abstract

Patients with systemic autoimmune rheumatic diseases, particularly RA, SLE, SS and idiopathic inflammatory myopathies, are at increased risk of developing malignancies. Cancer occurrence adds to the disease burden in these patients, adversely affecting quality of life and life expectancy. This risk is related to the pathobiology of the underlying rheumatic disease including the inflammatory burden, immunological defects, and personal and environmental exposure such as smoking and some viral infections. Immunomodulatory therapies, especially chemotherapeutic agents, are also associated with an increased risk of cancer in these conditions. The decision to use immunomodulating therapies in patients with rheumatic disease must take into account the disease severity, expectations for disease control, comorbidities and host and environmental risk factors for cancer. Effective screening and monitoring strategies are important in reducing the risk of cancer in these patients.

PMID:
22829694
DOI:
10.1093/rheumatology/kes189
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center